• Joanna P MacEwan, Lauren M Zhao, Katie Everson, Larry Liu, Dominik Lautsch, Fang Sun, and Darius N Lakdawalla.
• PRECISIONheor, 11100 Santa Monica Blvd, Ste 500, Los Angeles, CA 90025. Email: Joanna.MacEwan@precisionvh.com.
• Am J Manag Care. 2021 Apr 1; 27 (4): 162-168.

ObjectivesTo assess the evolving landscape of low-density lipoprotein cholesterol-lowering therapies (LLTs) and quantify their effect on cardiovascular disease (CVD)-related mortality and morbidity.Study DesignSecondary data came from LLT clinical trials and 1999-2014 National Health and Nutrition Examination Survey (NHANES) data. 1996-2016 Medical Expenditure Panel Survey (MEPS) data were used to estimate LLT spending. Nonfatal CVD events prevented by LLTs were calculated from clinical trials and NHANES. The value of nonfatal events prevented was calculated as the product of event treatment costs and the number of events prevented. The value of mortality reduction was calculated as the product of a value of a life-year and the life expectancy gain from LLTs. This was compared with LLT spending estimated using MEPS.MethodsTotal LLT expenditures were calculated based on MEPS LLT utilization and expenditure data. Values of prevented hospitalizations, prevented CVD events, and other LLT utilization-related outcomes were pulled from the published literature.ResultsCombined, statins and ezetimibe prevented 2.8 million nonfatal heart attacks and 1.7 million nonfatal strokes from 1999 to 2014. Statin use generated $2.6 trillion in societal value through CVD deaths avoided from 1987 to 2014, and 85% accrued to patients.ConclusionsLLTs have yielded significant societal value, and the majority of this value has accrued to patients.

7 keywords...

hide…